Potential treatment for most common form of muscular dystrophy

March 18, 2015 by Josh Barney, University of Virginia
Dr. Mani S. Mahadevan first identified the gene responsible for myotonic muscular dystrophy and now has come up with a potential new treatment for the disease.

A doctor who was one of the discoverers of the gene responsible for myotonic muscular dystrophy has now identified a drug that could slow the progression of muscle damage and muscle dysfunction associated with the disease – issues that cause patients significant disability and deterioration in quality of life.

The potential treatment is an experimental currently being evaluated for treating other conditions, such as rheumatoid arthritis. In lab tests, mice with that were given the treatment had better muscle function in tests such as running on a treadmill and had improved grip strength. In addition, their muscles became healthier and, notably, many even lived longer. While more testing needs to be done, Dr. Mani S. Mahadevan of the University of Virginia School of Medicine, is hopeful about the drug's potential in humans as well.

"The nice thing about this therapy is that we know that it's already been shown to be safe, because have already been done with it for other conditions. That's a big, big hurdle that's been overcome," he said. "With a lot of drugs, the problem is that once you do these proof-of-concept studies, the drugs need to be developed a lot further, refined and tested for safety and efficacy. But a lot of that work has been done, so therefore we can leapfrog the development of this therapy so that it can be moved into clinical trials sooner."

Mahadevan, of U.Va.'s Department of Pathology, has been conducting pioneering research into the causes of myotonic dystrophy, the most common form of , for more than two decades. His work revealed that the condition is caused by an expanding piece of DNA – a mutation that grows worse with each generation. Many people, he noted, do not even realize they have the mutation until a child or grandchild is born with a severe form of the disease.

In his latest discovery, Mahadevan and his team determined that in both mice and people with myotonic dystrophy, their muscles exhibit excessive activity of a cellular protein called TWEAK and its receptor, Fn14. And not only are the activity levels high in these tissues, they correlate with the severity of the disease symptoms.

With that discovery, Mahadevan approached the biotech company Biogen Idec, which had a longstanding interest in the TWEAK pathway, to see if the company had a therapy that could block the activity. Biogen Idec had just such a drug in development. After a multi-year collaboration with the company, Mahadevan and his team were able to show that this drug reduced the symptoms of myotonic dystrophy in mice – thus illuminating a path toward the first potential treatment for the debilitating muscle wasting seen in humans.

The drug has not yet been approved by the Food and Drug Administration, and therefore is not available to patients. The next steps would be for the drug to be tested in myotonic dystrophy patients as part of a clinical trial to determine if it is effective. Mahadevan isn't sure when such a trial might begin.

He notes that the drug might be used as a treatment for myotonic dystrophy on its own or possibly in conjunction with other approaches that are in the pipeline. "There's a lot of excitement within the patient community and within the field of researchers who are working on myotonic dystrophy right now," Mahadevan said. "There's a lot of hope."

A paper outlining the findings has been published online by the journal Human Molecular Genetics.

Explore further: Muscular dystrophy: Repair the muscles, not the genetic defect

More information: "TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy" Hum. Mol. Genet. (2015) 24 (7): 2035-2048 first published online December 11, 2014 DOI: 10.1093/hmg/ddu617

Related Stories

Muscular dystrophy: Repair the muscles, not the genetic defect

September 14, 2014
A potential way to treat muscular dystrophy directly targets muscle repair instead of the underlying genetic defect that usually leads to the disease.

Hope for muscular dystrophy patients: Harnessing gene helps repair muscle damage

January 15, 2015
Researchers have successfully improved the ability of muscle to repair itself - by artificially increasing levels of the BMI1 gene in the muscle-specific stem cells of mice with muscular dystrophy.

Cardiac and respiratory function supported by abdominal muscles in muscular dystrophy

February 27, 2015
The muscular dystrophies are known to target various muscle groups differentially. In addition to making limb muscles weak, muscular dystrophy (MD) can also lead to decreased function of specific muscles involved in respiration ...

Recent findings hold new implications for the pathogenesis of myotonic dystrophy

September 12, 2012
An important breakthrough could help in the fight against myotonic dystrophy. The discovery, recently published in the prestigious scientific journal Cell, results from an international collaboration between researchers at ...

Drug delivery strategy eliminates myotonia symptoms in mice with myotonic dystrophy

February 22, 2013
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease. ...

Recommended for you

Researchers discover key gene in cells associated with age-related hearing loss

November 21, 2018
An international group of researchers, led by Ronna Hertzano, MD, Ph.D., Associate Professor, Department of Otorhinolaryngology-Head & Neck Surgery, Anatomy and Neurobiology, at the University of Maryland School of Medicine ...

Study bridges a divide in cell aging in neurodegenerative diseases

November 21, 2018
Research from the University of Toronto has shown that in some neurodegenerative diseases, two hallmarks of cell aging – protein aggregation and a type of DNA instability – are linked. They were previously thought to ...

New method for studying gene expression could improve understanding of brain disease

November 21, 2018
It takes a lot of cells to make a human brain. The organ houses not only an enormous quantity of neurons (tens of billions), but also an impressive diversity of neuron types. In recent years, scientists have been developing ...

Parental 'feeding styles' reflect children's genes

November 20, 2018
New research from King's College London and UCL challenges the idea that a child's weight largely reflects the way their parents feed them. Instead, parents appear to adopt feeding styles in response to their children's natural ...

Scientists identify new genetic causes linked to abnormal pregnancies and miscarriages

November 20, 2018
A team of scientists at the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University have identified three genes responsible for recurrent molar pregnancies, a rare complication that occurs ...

A study suggests that epigenetic treatments could trigger the development of aggressive tumours

November 20, 2018
A study headed by the Institute for Research in Biomedicine (IRB Barcelona) and published in the journal Nature Cell Biology examined whether the opening of chromatin (a complex formed by DNA bound to proteins) is the factor ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.